Cargando...
MK-2206 Causes Growth Suppression and Reduces Neuroendocrine Tumor Marker Production in Medullary Thyroid Cancer through Akt Inhibition
BACKGROUND: Development of targeted therapies for medullary thyroid cancer (MTC) has focused on inhibition of the RET (Rearranged during Transfection) proto-oncogene. Akt has been shown to be a downstream target of RET via the key mediator phosphoinositide-3-kinase. MK-2206 is an orally administered...
Gardado en:
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2013
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3955957/ https://ncbi.nlm.nih.gov/pubmed/23900743 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-013-3168-2 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|